MARKET

LXEO

LXEO

Lexeo Therapeutics Inc
NASDAQ
4.750
+0.050
+1.06%
After Hours: 4.750 0 0.00% 16:31 06/26 EDT
OPEN
4.690
PREV CLOSE
4.700
HIGH
4.920
LOW
4.665
VOLUME
2.34M
TURNOVER
--
52 WEEK HIGH
10.99
52 WEEK LOW
3.600
MARKET CAP
372.98M
P/E (TTM)
-3.2677
1D
5D
1M
3M
1Y
5Y
1D
Lexeo Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 3d ago
Lexeo Therapeutics Price Target Cut to $9.00/Share From $12.00 by JP Morgan
Dow Jones · 3d ago
JP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $9
Benzinga · 3d ago
Lexeo Therapeutics price target lowered to $9 from $12 at JPMorgan
TipRanks · 3d ago
Lexeo Therapeutics's LX2006 Has A Viable Regulatory Pathway And Timeline
Seeking Alpha · 6d ago
Weekly Report: what happened at LXEO last week (0615-0619)?
Weekly Report · 6d ago
Lexeo Therapeutics Reports Data For LX2006 Gene Therapy In Friedreich Ataxia, Pivotal SUNRISE-FA 2 Study On Track For 2026 Launch, Publishid In The JAMA Cardiology
Benzinga · 06/17 20:04
Lexeo says LX2006 Phase I/II Friedreich ataxia data show early efficacy in JAMA Cardiology publication
PUBT · 06/17 20:01
More
About LXEO
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Webull offers Lexeo Therapeutics Inc stock information, including NASDAQ: LXEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXEO stock methods without spending real money on the virtual paper trading platform.